ClinVar Miner

Submissions for variant NM_152269.5(MTRFR):c.244G>A (p.Val82Met)

gnomAD frequency: 0.00002  dbSNP: rs374311195
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000196324 SCV000251227 uncertain significance not provided 2014-04-23 criteria provided, single submitter clinical testing p.Val82Met (GTG>ATG): c.244 G>A in exon 2 of the C12ORF65 gene (NM_152269.4)A variant of unknown significance has been identified in the C12ORF65 gene. The V82M variant has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. The V82M variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. This substitution occurs at a position that is conserved across species. In silico analysis predicts this variant is probably damaging to the protein structure/function. Missense mutations in this gene have not been reported as pathogenic. Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic mutation or a rare benign variant. The variant is found in MITONUC-MITOP panel(s).
Labcorp Genetics (formerly Invitae), Labcorp RCV002228874 SCV002509516 uncertain significance Combined oxidative phosphorylation defect type 7; Spastic paraplegia 2022-08-19 criteria provided, single submitter clinical testing This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 82 of the C12orf65 protein (p.Val82Met). This variant is present in population databases (rs374311195, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with C12orf65-related conditions. ClinVar contains an entry for this variant (Variation ID: 214191). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C15"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.